Preparation and Clinical evaluation of the combined solution of minoxidil, azelaic acid and spironolactone in the treatment of androgenic alopecia

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200115046143N3

Enrollment

Registered

2025-10-18

Start date

2025-10-22

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Androgenic Alopecia. Androgenic alopecia

Interventions

Intervention 1: Intervention group: They will receive a solution containing minoxidil 5%, spironolactone 5%, and azelaic acid 1.5% twice daily for three months. Intervention 2: Control group: The pati

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Diagnosis of androgenetic alopecia and its severity Informed consent of the patient No specific underlying diseases Absence of other skin diseases

Exclusion criteria

Exclusion criteria: Sensitivity to soluble components Diabetic patients with heart failure Pregnancy during the study Side effects that are not tolerated by the patient Immune deficiency Malignant diseases

Design outcomes

Primary

Measure	Time frame
Incidence and severity of Androgenic Alopecia. Timepoint: Before and up to 3 months after the intervention. Method of measurement: World Health Organization Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Yaser Vafaei

Hamedan University of Medical Sciences

y.vafaei@umsha.ac.ir+98 81 3838 1590

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026